JP2010538091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538091A5 JP2010538091A5 JP2010524187A JP2010524187A JP2010538091A5 JP 2010538091 A5 JP2010538091 A5 JP 2010538091A5 JP 2010524187 A JP2010524187 A JP 2010524187A JP 2010524187 A JP2010524187 A JP 2010524187A JP 2010538091 A5 JP2010538091 A5 JP 2010538091A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- aryl
- heterocycle
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 368
- 229910052739 hydrogen Inorganic materials 0.000 claims description 213
- 239000001257 hydrogen Substances 0.000 claims description 213
- 125000000217 alkyl group Chemical group 0.000 claims description 208
- 125000003118 aryl group Chemical group 0.000 claims description 192
- 150000001875 compounds Chemical class 0.000 claims description 184
- 125000003107 substituted aryl group Chemical group 0.000 claims description 164
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 154
- 150000002431 hydrogen Chemical class 0.000 claims description 148
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 132
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 112
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 112
- 125000003342 alkenyl group Chemical group 0.000 claims description 66
- 125000000304 alkynyl group Chemical group 0.000 claims description 66
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 66
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 66
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 65
- 241000124008 Mammalia Species 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 24
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 14
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 14
- 102000001253 Protein Kinase Human genes 0.000 claims description 13
- 108060006633 protein kinase Proteins 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 11
- 206010017758 gastric cancer Diseases 0.000 claims description 11
- 201000010536 head and neck cancer Diseases 0.000 claims description 11
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 11
- 201000011549 stomach cancer Diseases 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 9
- 210000002536 stromal cell Anatomy 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 206010003571 Astrocytoma Diseases 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 7
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 7
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 208000017604 Hodgkin disease Diseases 0.000 claims description 7
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 7
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 7
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 7
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 7
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 7
- 201000002510 thyroid cancer Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims description 6
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims description 6
- 238000011319 anticancer therapy Methods 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000002071 myeloproliferative effect Effects 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims description 4
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940000406 drug candidate Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims description 4
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 150000003222 pyridines Chemical class 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229940120638 avastin Drugs 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229940082789 erbitux Drugs 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 208000037964 urogenital cancer Diseases 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 230000006041 cell recruitment Effects 0.000 claims 2
- -1 pyridine compound Chemical class 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 12
- 0 *C(*)C(c(c(*)c1*)c(*)c(C2)c1N(*)C2=O)=CO Chemical compound *C(*)C(c(c(*)c1*)c(*)c(C2)c1N(*)C2=O)=CO 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97041007P | 2007-09-06 | 2007-09-06 | |
| US60/970,410 | 2007-09-06 | ||
| US1338907P | 2007-12-13 | 2007-12-13 | |
| US61/013,389 | 2007-12-13 | ||
| US7429508P | 2008-06-20 | 2008-06-20 | |
| US61/074,295 | 2008-06-20 | ||
| PCT/US2008/075418 WO2009033033A2 (en) | 2007-09-06 | 2008-09-05 | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013272195A Division JP5701372B2 (ja) | 2007-09-06 | 2013-12-27 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010538091A JP2010538091A (ja) | 2010-12-09 |
| JP2010538091A5 true JP2010538091A5 (enExample) | 2011-10-27 |
| JP5452490B2 JP5452490B2 (ja) | 2014-03-26 |
Family
ID=40429714
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524187A Expired - Fee Related JP5452490B2 (ja) | 2007-09-06 | 2008-09-05 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
| JP2013272195A Expired - Fee Related JP5701372B2 (ja) | 2007-09-06 | 2013-12-27 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
| JP2015028165A Expired - Fee Related JP5974124B2 (ja) | 2007-09-06 | 2015-02-17 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
| JP2016140101A Expired - Fee Related JP6495868B2 (ja) | 2007-09-06 | 2016-07-15 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
| JP2019021397A Pending JP2019070051A (ja) | 2007-09-06 | 2019-02-08 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013272195A Expired - Fee Related JP5701372B2 (ja) | 2007-09-06 | 2013-12-27 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
| JP2015028165A Expired - Fee Related JP5974124B2 (ja) | 2007-09-06 | 2015-02-17 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
| JP2016140101A Expired - Fee Related JP6495868B2 (ja) | 2007-09-06 | 2016-07-15 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
| JP2019021397A Pending JP2019070051A (ja) | 2007-09-06 | 2019-02-08 | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US8299106B2 (enExample) |
| EP (2) | EP3037419B1 (enExample) |
| JP (5) | JP5452490B2 (enExample) |
| CN (1) | CN101848908B (enExample) |
| CA (1) | CA2736177A1 (enExample) |
| CY (1) | CY1118012T1 (enExample) |
| DK (1) | DK2197878T3 (enExample) |
| ES (2) | ES2759347T3 (enExample) |
| HR (1) | HRP20161114T1 (enExample) |
| HU (1) | HUE030774T2 (enExample) |
| LT (1) | LT2197878T (enExample) |
| PL (1) | PL2197878T3 (enExample) |
| PT (1) | PT2197878T (enExample) |
| SI (1) | SI2197878T1 (enExample) |
| WO (1) | WO2009033033A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2197878T3 (en) * | 2007-09-06 | 2016-11-14 | Boston Biomedical Inc | FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases |
| TW201511499A (zh) * | 2007-12-10 | 2015-03-16 | Interdigital Patent Holdings | 無縣電鏈路控制封包丟棄及無線電鏈路控制重建觸發方法及裝置 |
| CA2865819A1 (en) | 2011-02-28 | 2013-09-07 | Mcmaster University | Treatment of cancer with dopamine receptor antagonists |
| US9550764B2 (en) | 2012-08-23 | 2017-01-24 | The Institute Of Cancer Research: Royal Cancer Hospital | Fused heterocyclic compounds and their use |
| US9187454B2 (en) | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| HK1220184A1 (zh) * | 2013-03-13 | 2017-04-28 | Boston Biomedical, Inc. | 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物 |
| US9227962B2 (en) | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
| US20160368870A1 (en) * | 2013-06-20 | 2016-12-22 | Boehringer Ingelheim International Gmbh | Olefin substituted oxindoles having ampk activity |
| JP6472096B2 (ja) * | 2014-01-27 | 2019-02-20 | ボストン バイオメディカル， インコーポレイテッド | 癌を処置するための新規方法 |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| EP3288552A1 (en) * | 2015-04-27 | 2018-03-07 | Boston Biomedical, Inc. | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor |
| JPWO2017026119A1 (ja) * | 2015-08-10 | 2018-05-24 | 大日本住友製薬株式会社 | ５−（チアゾール−４−イル）インドリン−２−オン誘導体の精製方法 |
| WO2017160978A1 (en) | 2016-03-15 | 2017-09-21 | Boston Biomedical, Inc. | Cell cultures and use thereof |
| WO2018005444A2 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| US12390460B2 (en) | 2018-09-18 | 2025-08-19 | 1Globe Biomedical Co., Ltd. | Treatment for obesity |
| BR112021005086A2 (pt) | 2018-09-18 | 2021-06-08 | 1Globe Biomedical Co., Ltd. | tratamento para doença hepática gordurosa não alcoólica |
| US20250129067A1 (en) | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2144403T3 (es) * | 1990-11-30 | 2000-06-16 | Otsuka Pharma Co Ltd | Derivados de tiazol como inhibidores de oxigeno activo. |
| WO1998007695A1 (en) * | 1996-08-23 | 1998-02-26 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| WO1999015524A1 (en) * | 1997-09-23 | 1999-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives |
| CN1329390C (zh) * | 2000-02-15 | 2007-08-01 | 苏根公司 | 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂 |
| WO2001064681A2 (en) * | 2000-02-28 | 2001-09-07 | Sugen, Inc. | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| EP1294688A2 (en) * | 2000-06-02 | 2003-03-26 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| JP4343534B2 (ja) * | 2001-03-02 | 2009-10-14 | ゲーペーツェー バイオテック アクチェンゲゼルシャフト | ３ハイブリッド・アッセイ・システム |
| WO2002081466A1 (en) | 2001-04-09 | 2002-10-17 | Sugen, Inc. | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| US20030119839A1 (en) * | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| CN1898205A (zh) * | 2003-10-24 | 2007-01-17 | 舍林股份公司 | 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途 |
| EP1973910B1 (en) * | 2006-01-27 | 2013-06-26 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyrrolo[3,2-c]pyridine-4-one 2-indolinone protein kinase inhibitors |
| ES2369315T3 (es) * | 2007-06-01 | 2011-11-29 | F. Hoffmann-La Roche Ag | Derivados de piperidina-amida. |
| DK2197878T3 (en) * | 2007-09-06 | 2016-11-14 | Boston Biomedical Inc | FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases |
| US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
-
2008
- 2008-09-05 DK DK08829600.9T patent/DK2197878T3/en active
- 2008-09-05 EP EP16156340.8A patent/EP3037419B1/en active Active
- 2008-09-05 SI SI200831667A patent/SI2197878T1/sl unknown
- 2008-09-05 WO PCT/US2008/075418 patent/WO2009033033A2/en not_active Ceased
- 2008-09-05 CA CA2736177A patent/CA2736177A1/en not_active Abandoned
- 2008-09-05 ES ES16156340T patent/ES2759347T3/es active Active
- 2008-09-05 LT LTEP08829600.9T patent/LT2197878T/lt unknown
- 2008-09-05 EP EP08829600.9A patent/EP2197878B1/en active Active
- 2008-09-05 PL PL08829600T patent/PL2197878T3/pl unknown
- 2008-09-05 HU HUE08829600A patent/HUE030774T2/hu unknown
- 2008-09-05 ES ES08829600.9T patent/ES2591028T3/es active Active
- 2008-09-05 PT PT88296009T patent/PT2197878T/pt unknown
- 2008-09-05 US US12/676,869 patent/US8299106B2/en not_active Expired - Fee Related
- 2008-09-05 HR HRP20161114TT patent/HRP20161114T1/hr unknown
- 2008-09-05 JP JP2010524187A patent/JP5452490B2/ja not_active Expired - Fee Related
- 2008-09-05 CN CN200880114705.9A patent/CN101848908B/zh active Active
-
2012
- 2012-08-27 US US13/595,708 patent/US20120321622A1/en not_active Abandoned
-
2013
- 2013-12-27 JP JP2013272195A patent/JP5701372B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-29 US US14/445,783 patent/US9725444B2/en not_active Expired - Fee Related
-
2015
- 2015-02-17 JP JP2015028165A patent/JP5974124B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-15 JP JP2016140101A patent/JP6495868B2/ja not_active Expired - Fee Related
- 2016-09-13 CY CY20161100904T patent/CY1118012T1/el unknown
-
2017
- 2017-07-07 US US15/643,608 patent/US20180022743A1/en not_active Abandoned
-
2018
- 2018-11-14 US US16/190,669 patent/US20190248781A1/en not_active Abandoned
-
2019
- 2019-02-08 JP JP2019021397A patent/JP2019070051A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010538091A5 (enExample) | ||
| CA2736177A1 (en) | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | |
| AU2018282363B2 (en) | Compounds and methods of use | |
| JP6038792B2 (ja) | 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体 | |
| JP5881705B2 (ja) | Ｎａｍｐｔの阻害のための新規化合物及び組成物 | |
| CA2799146C (en) | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | |
| JP5781934B2 (ja) | チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物 | |
| CN111467346B (zh) | 具有四氢吡喃基甲基的吡啶酮衍生物 | |
| CN114025755B (zh) | 以杂环化合物作为激酶抑制剂的治疗用途 | |
| Torres et al. | Imidazoles and benzimidazoles as tubulin-modulators for anti-cancer therapy | |
| JP2017031207A (ja) | 置換６，６−縮合窒素複素環化合物及びその使用 | |
| Aziz et al. | Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2, 4-diones bearing heterocyclic rings as dual VEGFR-2/EGFR T790M tyrosine kinase inhibitors | |
| JP2010526096A5 (ja) | キナーゼ阻害剤として有用なチアゾールおよびピラゾール | |
| JP2011511095A5 (enExample) | ||
| CN102014627A (zh) | 作为极光激酶抑制剂的稠合双环嘧啶化合物 | |
| JP4973190B2 (ja) | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 | |
| EP3873474A1 (en) | Heterocyclic compounds as bet inhibitors | |
| WO2007065010A2 (en) | Anti-angiogenesis compounds | |
| Abd El-Mawgoud et al. | Design, synthesis and cytotoxic evaluation of new thieno [2, 3-d] pyrimidine analogues as VEGFR-2/AKT dual inhibitors, apoptosis and autophagy inducers | |
| JPWO2020102646A5 (enExample) | ||
| AU2020414132B2 (en) | Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof | |
| JP5161072B2 (ja) | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 | |
| CN113135909B (zh) | Dpd抑制剂及其制备方法、药物组合物和用途 | |
| WO2012125447A2 (en) | Piperazinedione compounds | |
| KR20180021783A (ko) | 갈리엘라락톤의 에테르 유사체 |